Ad is loading...
MENU

EDIT Stock Editas Medicine (EDIT, $2.44) RSI Indicator left the oversold zone on November 22, 2024

A.I.dvisor
at Tickeron.com
Loading...
EDIT - Editas Medicine
RSI signal
Bullish Trend
Odds of UP Trend
Tickeron
RSI signal
Price: $2.44
Daily change: +$0.07 (+2.95%)
Daily volume: 2.3M
Capitalization: $201.4M
Industry: Biotechnology
This is a signal that EDIT's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options. A.I.dvisor looked back and found 44 similar cases where EDIT's RSI Indicator left the oversold zone, and in of them led to a successful outcome. Odds of Success:

Momentum Indicator for EDIT turns negative, indicating new downward trend

EDIT saw its Momentum Indicator move below the 0 level on November 12, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In of the 95 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 14, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

EDIT moved below its 50-day moving average on October 22, 2024 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for EDIT entered a downward trend on November 22, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where EDIT's RSI Indicator exited the oversold zone, of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in of 251 cases, the price rose further within the following month. The odds of a continued upward trend are .

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.147) is normal, around the industry mean (13.913). P/E Ratio (0.000) is within average values for comparable stocks, (89.373). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.810). EDIT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.245) is also within normal values, averaging (226.220).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
EDIT
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
265
Web
https://www.editasmedicine.com